Highest-materiality recent filing
BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC
Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.
BioCorRx raises $200K via note, warrant & inducement shares; note matures Sep 2024
Issued $220K principal note (8% OID) for $200K cash; unsecured, matures Sep 8, 2024.
BioCorRx raises $1M via private placement of 229,886 shares at $4.35/share to two directors
Gross proceeds of $1M from sale of 229,886 shares at $4.35 per share to Lucido and Galligan trusts.
BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant
Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.
Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “ Murthy Resignation ”).
On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “ Board ”) of BioCorRx Inc. (the “ Company ”), effective March 31, 2024 (the “ Granier Resignation ”).
On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024
On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024
On October 30, 2023, the board of directors (the “Board”) of BioCorRx Inc. (the “Company”) approved Brady Granier’s request for a paid administrative leave of absence from his position as the President of the Company for the period between October 30, 2023 and January 30, 2024.
On January 20, 2023, BioCorRx, Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”).
Max materiality 0.75 · Median 0.50 · Most common event other_material